BDPC (systematic name 4-(4-bromophenyl)-4-(dimethylamino)-1-(2-phenylethyl)cyclohexanol; also known as bromadol) is a potent fully synthetic
opioid with a distinctive
arylcyclohexylaminechemical structure. It was developed by Daniel Lednicer at Upjohn in the 1970s.[1] Initial studies estimated that it was around 10,000 times the potency of
morphine in animal models.[2] However, later studies using more modern techniques assigned a value of 504 times the potency of morphine for the more active trans-isomer.[3] This drug was first seized along with three kilograms of
acetylfentanyl in an April 25, 2013 police action in Montreal, Canada,[4] and has reportedly continued to be available on the
designer drug market internationally.[5][6] Analogues where the para-bromine is replaced by chlorine or a methyl group retain similar activity, while the meta-hydroxyl derivative demonstrated robust antagonist activity.[7][8]
^US 4366172, Lednicer, Daniel, "4-Amino-cyclohexanols, their pharmaceutical compositions and methods of use", issued 1982-12-28, assigned to
Upjohn Company
^Lednicer D, VonVoigtlander PF (October 1979). "4-(p-Bromophenyl)-4-(dimethylamino)-1-phenethylcyclohexanol, an extremely potent representative of a new analgesic series". Journal of Medicinal Chemistry. 22 (10): 1157–8.
doi:
10.1021/jm00196a001.
PMID513062.
^Lednicer D, VonVoigtlander PF, Emmert DE (April 1981). "4-amino-4-arylcyclohexanones and their derivatives: a novel class of analgesics. 2. Modification of the carbonyl function". Journal of Medicinal Chemistry. 24 (4): 404–8.
doi:
10.1021/jm00136a010.
PMID7265128.